Pt Prodia Widyahusada Tbk · IDX:PRDA
Pt Prodia Widyahusada Tbk — FY2022 Earnings Presentation
32 slides from Pt Prodia Widyahusada Tbk's earnings presentation, 2023
Slide 1: FY 2022 Results Update
FY 2022 Results Update PT. PRODIA WIDYAHUSADA TBK
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by PT Prodia Widyahusada (the "Company") solely for use in connection with the analyst presentation relating to the Company. The information contained in this presentation is strictly confidential and is provided to you solely for your reference. By vie
Slide 3: Corporate Overview
= ww 4 | & CORPORATE OVERVIEW
Slide 4: Performance Highlight in 2022
Performance Highlight in 2022 Facing a normalization, PRDA still able to maintain its revenue, visit, and volume in 2022 • 50 years experience in Clinical Lab IDR 2.18 Trillion Industry since 1973 FY2022 Revenue (-17.7% yoy), CAGR 3yrs (+7.7%) • Has the most recognized Brand in >2.8 million Indonesi
Slide 5: Extensive Milestone to Grow
Extensive Milestone to Grow ▪ Received SMK3 accreditation • Establishment of Prodia National Became the first and and OHSAS 2015 Referral Lab, the first Indonesian only lab in Indonesia to ▪ Opened the first green Became the first clinical lab clinic to receive SNI ISO 15189 laboratory in Indonesia
Slide 6: Extensive Milestone to Grow
Extensive Milestone to Grow 2017 2018 2019 2020 2021 2022 Focus on Quality Launched Next Applied The first private lab New Test New Test Diagnostic: Generation Lab Lab Automation: in Indonesia that Development from Development from Next- • Received Westgaard & Genomics Lab: • Total Laboratory using
Slide 7: Experienced Management Team
Experienced Management Team With more than 20 years experience in delivering growth and innovation of Prodia Years of Years of Years of Years of Years of 50 Experience 50 Experience 39 Experience 48 Experience 31 Experience Gunawan Endang Joseph Fellipus Keri Keri Lestari Lestari Dandan Andi Wijaya
Slide 8: Shareholder Composition
Shareholder Composition PT Prodia Utama Bio Majesty Pte. Ltd. Public Public 57% 15% 28% Distributor for Contract Research, therapy Distributor for medical Research and banking of healthcare equipment Organization stem cell products PT Prodia Widyahusada Tbk Nationwide Outlet Network across Indonesia
Slide 9: Investment Highlight
INVESTMENT HIGHLIGHT
Slide 10: Largest Independent Labs Chain
Largest Independent Labs Chain Market Share by Revenue Prodia vs Total Independent Labs Independent Clinical Labs (2020 & 2021) (Billion IDR) 3YRS CAGR 3YRS CAGR 39.5% 37.9% 26.0% 33.1% 23.9% 27.8% 7,225 2020 2021 2,737 4,551 4,874 1,782 1,926 32.7% 29.0% Prodia Next 5 Players Combined Others 2019 2
Slide 11: Strong Operational Track Record
Strong Operational Track Record VISITS (in million) REVENUE (in IDR trillion) 2.18 2.8 CAGR 2.4% CAGR 8.3% 2.5 1.47 Prodia has generated continuous 2017 2018 2019 2020 2021 2022 2017 2018 2019 2020 2021 2022 revenue growth and increasing REVENUE PER VISIT (in IDR „000) EBITDA (in IDR Billion) number
Slide 12: Comprehensive Service Offering
Comprehensive Service Offering Routine Testing Non-Laboratory Testing Specialty Clinics Esoteric Testing Referral Lab Services Doctor Consultation One-stop shop, offering the most General Medical Genomic Testing Check-Up Services Preventive Treatment comprehensive range of clinical lab tests in Indo
Slide 13: Scalable Hub & Spoke Business Model
Scalable Hub & Spoke Business Model 4 Referral Labs in Jakarta, Surabaya, Medan, Makassar Significant Economies of Scale Achieved Centralized information “Hub and spoke” model offers Prodia Clinical Labs, Prodia Referral with integrated IT Hospitals and Other Clinics scalable platform reducing Lab S
Slide 14: Strong Relationship with Medical Community
Strong Relationship with Medical Community Strong relationships through the Introduced new tests, such as NIPT ProSafe, Amino work of more than 500 Marketing Acid Profile, Fatty Acid Profile, CArisk, DIArisk, Liquid and Laboratory Information biopsy EGFR Mutation, New Born Screening, 17OH Service pe
Slide 15: Pioneer in New Lab Testing; Digital Healthcare Platform
Pioneer in New Lab Testing Offer more than 3,000 type of testing, with referral Target to launch minimum 10 Partnership to NUH Singapore and Quest Diagnostic US new testing every year One of The Largest Digital Healthcare Platform Walk-in Apps Doctor Referral Apps One Stop Health Solution Apps Prodi
Slide 16: Market Overview & Growth Strategy
ws y 4 MARKET — OVERVIEW & GROWTH | STRATEGY
Slide 17: 2023 Indonesia Economic Outlook
2023 Indonesia Economic Outlook Stay Resilient with Positive Growth Forecast 4.5% – 5.3% Indonesia‟s GDP Growth Projection for 2023 GDP Growth Projection 2023 Indonesia World Indonesia’s Govt’ 4.5% - 5.3% 2.3% World Bank 4.8% 1.7% Organization for Economic Cooperation 4.7% 2.2% and Development (OECD
Slide 18: Indonesia's Healthcare Market
Indonesia‟s Healthcare Market Focusing more on preventive treatment and with the opportunity to tap in digitalization As the COVID-19 cases began to decrease, The Ministry of Health has focusing its The development of Indonesia Digital Healthcare Market creates good opportunity budget allocation mor
Slide 19: Company's Growth Strategy
Company‟s Growth Strategy Expand our presence and grow our Build new growth pillars network of outlets in both physical and digital channel in Indonesia Orchestrate highest quality health ecosystem and leading digital health ecosystem in Indonesia Upgrade existing clinical laboratories to provide wi
Slide 20: Leader in Next Generation Technology
Leader in Next Generation Technology Research Evaluation Laboratory Laboratory Mass Spectrometry & Molecular Separation Next Generation Diagnostic Science Laboratory Laboratory Laboratory Anatomical Flow Pathology Cytometry Laboratory Laboratory Personalized Treatment and The Concept of Precision Me
Slide 21: Prodia's Impact to Community
Prodia's Impact to Community Prodia delivers impact through initiatives to achieve sustainable business growth in creating added value for stakeholders including shareholders, customers, medical personnel, regulators, the communities and the environment. This program contains our contribution in the
Slide 22: Business Update
a ww 4 | & BUSINESS UPDATE |
Slide 23: Deliver Solution for Customer Needs with Customer Centric Model
Deliver Solution for Customer Needs with Customer Centric Model • Routine, Esoteric, Genomic Tests • Wellness Package Professional Contact Centre • Disease Screening • Call Centre 1500-830 Package • Chat Whatshapp 0855-1500-830 • Chat bot TANIA (Tanya Prodia) • Prodia Mobile Customer can book and pa
Slide 24: New Apps Launching – U by Prodia
New Apps Launching – U by Prodia Managed by PT Prodia Digital Indonesia, U by Prodia is a comprehensive digital health service to provide one-stop digital health solution for its customer. 19
Slide 25: Digital Diagnostic Partner for Doctor
Digital Diagnostic Partner for Doctor Giving effectiveness and easiness for Doctor in manage the patient’s health report Prodia Mobile for Doctor apps assist doctors to create testing referral to all Prodia’s Lab Services, provides live chat and manage their patient’s online health report. Launched
Slide 26: Outlet Development
Outlet Development 2016-2022 Outlet Development 283 292 287 267 259 276 2023 Outlet Development Target 259 2 5 7 4** 4** 4** 4** 9 11 14 12 9 11 14 1-2 20 108 98 113 118 130 128 122 Clinical Labs POC Outlets 1-2 1 148 148 148 129 136 143 147 Hospital Labs Specialty Clinic “Prodia not only focus to d
Slide 27: FY2022 Revenue
FY2022 Revenue Revenue (Audited) Quarterly Revenue (Unaudited) In IDR Billion In IDR Billion FY17-FY22 CAGR +8.3% 2017 2018 2019 2020 2021 2022 FY21-FY22 FY22 revenue was growth: -17.7% normalized after a hike in 2021 due to unusual check-up demand. 2,652.3 4Q22 : 3Q22 : 601.6 In 1Q22, there was
Slide 28: Financial Update
ws ay FINANCIAL UPDATE
Slide 29: FY2022 Gross Profit & Net Income
FY2022 Gross Profit & Net Income Gross Profit (in IDR Billion) Net Income (in IDR Billion ) FY17-FY22 CAGR +9.2% FY17-FY22 CAGR +19.8% FY21-FY22 Net Income Margin Gross Profit Margin FY21-FY22 growth: -18.7% growth: -40.4% 1632.7 623.2 1327.1 23.5% 1041.0 1046.2 371.6 942.8 61.6% 853.5 60.8% 268.7 5
Slide 30: FY2022 COGS & OPEX
FY2022 COGS & OPEX COGS (in IDR Billion ) OPEX (in IDR Billion ) FY17-FY22 CAGR +6.9% FY17-FY22 CAGR +4.5% COGS to revenue Opex to revenue Direct Cost G&A Expense FY21-FY22 FY21-FY22 Indirect Cost Marketing Expense growth: +1.6% growth: -16.2% 146 42 46 50 46 30 125 157 41 126 44.2% 101 114 48.6% 48
Slide 31: FY2022 Financial Summary
FY2022 Financial Summary (in IDR Bn) FY2022 FY2021 Change (in IDR Bn) FY2022 FY2021 Change Revenue 2,181.6 2,652.3 -17.7% Total Asset 2,669.6 2,702.2 -2.9% Total Equity 2,311.1 2,310.4 +5.5% Gross Profit 1,327.1 1,632.7 -18.7% EBIT 447.0 758.7 -41.1% EBT 470.3 788.6 -40.4% Net Income 371.6 623.2 -40
Slide 32: Thank You!
THANK YOU! For more Information : PT Prodia Widyahusada Tbk investor.relation@prodia.co.id Prodia Tower, Jl. Kramat Raya No. 150 Jakarta 10430, Indonesia www.prodia.co.id